Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Abciximab local infusion
Atrium Therapeutics
Acute Anterior Myocardial Infarction
1 trial -
Acalabrutinib
The First People's Hospital of Lianyungang
Chronic Lymphocytic Leukemia
1 trial -
Aprepitant 0mg
BRIGHT MINDS BIOSCIENCES INC.
Narcotic Abuse
1 trial -
Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
The First People's Hospital of Lianyungang
Ovarian Cancer
1 trial -
Atorvastatin 20 Mg Oral Tablet
The First People's Hospital of Lianyungang
Atherosclerotic Cardiovascular Disease
1 trial -
Atorvastatin Calcium 20Mg Tab
The First People's Hospital of Lianyungang
Hyperlipidemias
1 trial -
Avatrombopag 20 MG Oral Tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aplastic Anemia
1 trial -
Benralizumab
Grace Therapeutics
Asthma; Eosinophilic
1 trial -
Bevacizumab
The First People's Hospital of Lianyungang
Brain Glioma
1 trial -
Blinatumomab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Adult ALL
1 trial -
Blinatumomab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-ALL
1 trial -
CYP2C19 genotype testing
Beijing Anzhen Hospital
Angina, Stable
1 trial -
Cadonilimab
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial -
Cambridge Weight Plan
United Therapeutics Europe Ltd
Diabetes
1 trial -
Canagliflozin
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus With Complication
1 trial -
Cannabis (30% THC Concentrate)
BRIGHT MINDS BIOSCIENCES INC.
THC
1 trial -
Carbon ion radiotherapy
Shanghai Proton and Heavy Ion Center
Pancreatic Cancer Non-resectable
1 trial -
Carrelizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Carrelizumab
The First People's Hospital of Lianyungang
Cholangiocarcinoma
1 trial -
Clopidogrel
BRIGHT MINDS BIOSCIENCES INC.
Metabolism of Clopidogrel
1 trial -
Clostridium butyricum (live) Tablets(Meiya)
Rocket Pharmaceuticals B.V.
Rectal Cancer
1 trial -
DPP4
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial -
Dapagliflozin
Hospital Authority, Hong Kong
Diabetes Mellitus, Type 2
1 trial -
Daratumumab
The First People's Hospital of Lianyungang
Antibody-mediated Rejection
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources